Phase II Docetaxel / Carboplatin / XRT + Surgical Resection in Stage III NSCLC

Trial ID or NCT#

NCT00238615

Status

not recruiting iconNOT RECRUITING

Purpose

The purpose of this study is to assess how well this particular combination of chemotherapy, radiation and surgery works to help people with locally advanced lung cancer, how well PET scans indicates whether someone has responded to chemotherapy and radiation, and gene expression patterns related to outcomes in patients with locally advanced lung cancer who receive this treatment regimen.

Official Title

A Phase II Trial of Concurrent Docetaxel (Taxotere) / Carboplatin / Radiotherapy Followed by Surgical Resection Followed by Consolidation Taxotere / Carboplatin in Stage III Non-Small Cell Lung Cancer (NSCLC)

Eligibility Criteria

Sexes Eligible for Study: ALL
Accepts Healthy Volunteers: No
Show Less

Investigator(s)

Heather Wakelee
Heather Wakelee
Medical oncologist, Thoracic specialist
Winston Chen and Phyllis Huang Professor

Contact us to find out if this trial is right for you.

Contact

Lisa Zhou
6507364112

View on ClinicalTrials.gov